News | May 31, 2013

Study evaluates the long-term outcomes of prostate cancer patients who received radiation treatments following prostatectomies.


May 31, 2013 — Intensity-modulated radiation therapy (IMRT) has become the most commonly used type of radiation in prostate cancer, but research from the University of North Carolina suggests that the therapy may not be more effective than older, less expensive forms of radiation therapy in patients who have had a prostatectomy.

The comparative effectiveness study, published online by JAMA Internal Medicine, evaluated the long-term outcomes of prostate cancer patients who received radiation treatments following prostatectomies using conformal radiation therapy (CRT) against the newer and more expensive IMRT.

Study lead Ronald Chen, M.D., MPH, assistant professor of radiation oncology in the UNC School of Medicine, said the results showed little difference in the long-term health of patients who used the newer and older radiation therapies.

“Many prostate cancer patients need radiation treatment after prostatectomy, the surgical removal of the prostate, either because the cancer is aggressive or for recurrence. In prostate cancer, we have seen a trend in our healthcare system where new technologies are adopted quickly, maybe because there is a belief that newer treatments are better, but often there is a lack of studies to actually compare patient outcomes from older versus newer treatments,” said Chen.

The study used Medicare data to compare the outcomes of 457 IMRT and 557 CRT patients treated between 2002 and 2007. The patients, 66 years of age or older who underwent radical prostatectomy and subsequent radiation therapy within three years of their surgery, showed no difference in regards to urinary side effects, bowel side effects, sexual dysfunction and other long-term side effects or cancer control.

“For patients with newly diagnosed prostate cancer who have chosen to receive curative radiation treatment, our prior study showed that IMRT was associated with less long-term side effects and better cancer control than CRT. However, for patients who have had a prostatectomy already, and subsequently need radiation treatment, this study shows that IMRT and CRT seemed to have similar outcomes,” said Chen.

A lot of men across the United States who need radiation therapy after prostatectomy are not getting it, according to Chen, and he speculates that the cost of treatment may play a factor. While research shows that as many as one-third to one-half of the patients undergoing surgery for prostate cancer may benefit from radiation treatments subsequently to achieve a cure, Chen said that the data show only 10 to 15 percent of those who could benefit actually receive the therapy.

“If 3-D conformal radiation provides an effective and safe treatment for these patients, then we can probably show that radiation is a very cost effective treatment and potentially remove one of the large obstacles to patients being able to get this necessary treatment after surgery,” said Chen.

For more information: archinte.jamanetwork.com


Related Content

News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
News | Radiation Oncology

July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
News | Radiology Business

July 3, 2024 — The American Society of Radiologic Technologists has launched the BeRAD Professionalism Award to ...

Time July 03, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
Subscribe Now